IBN | ||
---|---|---|
OUTLOOK RATING 1..100 | 63 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 82 Overvalued | |
PROFIT vs RISK RATING 1..100 | 6 | |
SMR RATING 1..100 | 1 | |
PRICE GROWTH RATING 1..100 | 60 | |
P/E GROWTH RATING 1..100 | 55 | |
SEASONALITY SCORE 1..100 | 49 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EMM | IBN | |
---|---|---|
RSI ODDS (%) | 2 days ago76% | 1 day ago69% |
Stochastic ODDS (%) | 2 days ago81% | 1 day ago64% |
Momentum ODDS (%) | 2 days ago90% | 1 day ago49% |
MACD ODDS (%) | 2 days ago81% | 1 day ago61% |
TrendWeek ODDS (%) | 2 days ago82% | 1 day ago56% |
TrendMonth ODDS (%) | 2 days ago85% | 1 day ago40% |
Advances ODDS (%) | 3 days ago83% | 6 days ago59% |
Declines ODDS (%) | 13 days ago82% | 9 days ago41% |
BollingerBands ODDS (%) | 2 days ago82% | 1 day ago68% |
Aroon ODDS (%) | 2 days ago85% | 1 day ago54% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
EMXC | 69.46 | 0.63 | +0.92% |
iShares MSCI Emerging Mkts ex China ETF | |||
QQQJ | 36.39 | 0.32 | +0.89% |
Invesco NASDAQ Next Gen 100 ETF | |||
EAOA | 41.06 | 0.21 | +0.51% |
iShares ESG Aware 80/20 Agrsv Allc ETF | |||
XPH | 48.43 | 0.09 | +0.19% |
SPDR® S&P Pharmaceuticals ETF | |||
MYCH | 25.08 | N/A | -0.02% |
SPDR SSGA My2028 Corporate Bond ETF |
A.I.dvisor tells us that EMM and GRAB have been poorly correlated (+12% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EMM and GRAB's prices will move in lockstep.
Ticker / NAME | Correlation To EMM | 1D Price Change % | ||
---|---|---|---|---|
EMM | 100% | +1.25% | ||
GRAB - EMM | 12% Poorly correlated | +1.44% | ||
VIST - EMM | 6% Poorly correlated | +1.04% | ||
GLOB - EMM | 3% Poorly correlated | +0.80% | ||
ITUB - EMM | 3% Poorly correlated | +0.29% | ||
IBN - EMM | 0% Poorly correlated | -0.90% | ||
More |